» Articles » PMID: 24820452

Quality of Life in Psoriasis Patients

Overview
Date 2014 May 14
PMID 24820452
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Patient-reported outcomes are major components of decision making in clinical research, reimbursement, health policy and health care for psoriasis. The most important construct in patient-reported outcomes is health-related quality of life (HRQoL) which encompasses the individual's well-being with respect to health. HRQoL cannot directly be measured but is assessed in single dimensions, especially physical, emotional, social and functional aspects. For this, disease- and condition-specific instruments are used. Psoriasis is a chronic inflammatory disease affecting the skin as well as other tissues and organ systems. Patients suffer from a large scale of impairments, for example, physical symptoms, stigmatization and embarrassment, psychological strain and disabilities in profession. Improvement of HRQoL is a major objective of disease management. Current knowledge on determinants of HRQoL and the treatments available increase QoL in clinical care.

Citing Articles

Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection.

Jauregui W, Abarca Y, Ahmadi Y, Menon V, Zumarraga D, Rojas Gomez M Cureus. 2024; 16(9):e68569.

PMID: 39364475 PMC: 11449469. DOI: 10.7759/cureus.68569.


Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.

Augustin M, Gottlieb A, Lebwohl M, Pinter A, Warren R, Puig L Dermatol Ther (Heidelb). 2024; 14(10):2841-2857.

PMID: 39285121 PMC: 11480266. DOI: 10.1007/s13555-024-01261-6.


A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar) in the management of psoriasis with scalp involvement.

Staubach P, Korber A, Trueb R, Mann C, von Kiedrowski R Drugs Context. 2024; 13.

PMID: 38770372 PMC: 11104291. DOI: 10.7573/dic.2024-1-6.


Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.

Megna M, Balato A, Caccavale S, Cacciapuoti S, Calabrese G, Di Brizzi E J Clin Med. 2024; 13(9).

PMID: 38731081 PMC: 11084800. DOI: 10.3390/jcm13092552.


Association of IL-17F rs763780 polymorphism and risk of psoriasis in Turkish population: a case-control study.

Akadam-Teker A, Aksan B An Bras Dermatol. 2024; 99(3):357-361.

PMID: 38331704 PMC: 11074563. DOI: 10.1016/j.abd.2023.06.006.